Halozyme Therapeutics reported $113.44M in Gross Profit on Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 110.02M 8.15M
Alnylam Pharmaceuticals ALNY:US $ 190.3M 35.75M
Amarin AMRN:US $ 122.33M 8.49M
Amgen AMGN:US $ 4889M 478M
Baxter International BAX:US $ 1242M 77M
Eli Lilly And LLY:US $ 4786.9M 140.1M
Esperion Therapeutics ESPR:US $ 38.86M 32.66M
Halozyme Therapeutics HALO:US $ 113.44M 42.63M
Intercept Pharmaceuticals ICPT:US $ 95.96M 15.11M
Intra Cellular Therapies ITCI:US $ 18.01M 3.58M
JAZZ PHA JAZZ:US $ 632.62M 65.22M
Mannkind MNKD:US $ 13.35M 3.53M
Nektar Therapeutics NKTR:US $ 20.66M 2.77M
Peregrine Pharmaceuticals PPHM:US $ 11.39M 3.25M
Pfizer PFE:US $ 11985M 1575M
Rigel Pharmaceuticals RIGL:US $ 26.14M 54.56M
United Therapeutics UTHR:US $ 409.3M 53.2M
Vanda Pharmaceuticals VNDA:US $ 61.33M 4.69M